Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

ABSTRACT:

Background

New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed.

Methods

We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria. The participants received L9LS either intravenously or subcutaneously at a dose of 1 mg, 5 mg, or 20 mg per kilogram of body weight. Within 2 to 6 weeks after the administration of L9LS, both the participants who received L9LS and the control participants underwent controlled human malaria infection in which they were e

SUBMITTER: Wu RL 

PROVIDER: S-EPMC9806693 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature